Here is Matt Lowdon‘s weekly deals and funding update for the medical devices and biotech markets. The top headlines I found include news from surgical robotics, gene therapy, drug delivery and more. Congratulations to all involved and let me know if I have missed anything.
🔔 Eye disease biotech Ollin Biosciences launches with $100M and sights set on Roche showdown.
🔔Stryker is linking up with Siemens Healthineers to develop a new robotic system aimed at treating emergencies such as strokes and aneurysms, as well as other procedures within the brain.
🔔Lisbon’s immuno-oncology company Mondego Bio has left stealth mode through a €20m Series A financing led by Biovance Capital
🔔California VC firm Aditum Bio is at it again, this time partnering up with China-based Mabwell Bioscience to launch a new biotech focused on cardiovascular disease with Kalexo Bio.
🔔CSL has signed an option and collaboration agreement with VarmX valued at up to US$2.2bn. The company will pay US$117m upfront and will fund a global Phase III trial of VMX-C001.
🔔VectorY pens $1.2B biobucks pact to use Shape Therapeutics Inc.‘s capsid to deliver gene therapies into brain.
🔔Biogen has given Alcyone Therapeutics Inc. a starring role in its drug delivery strategy, paying $85 million to buy the biotech and take control of an implant for getting medicines into the spinal canal.
🔔Enhanced Genomics concludes $19m Series A haul to map whole-genome 3D interactions
🔔Aevice Health, a leading provider of remote monitoring solutions for chronic respiratory disease management today announced that it has raised US$7M Seed Plus Round
🔔Roche has signed a definitive merger agreement to acquire 89bio and its Phase III candidate pegozafermin for $3.5bn.
#medicaldevices #biotechnology #therapeutics #surgicalrobotics #genetherapy
